Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort Study.
[PURPOSE] Metaplastic breast cancer (metBC) is a rare subtype of breast cancer known for its challenging management.
- 95% CI 0.83-1.82
- HR 1.23
- 추적기간 54 months
APA
Bergman M, Schiza A, et al. (2026). Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort Study.. Cancer medicine, 15(2), e71570. https://doi.org/10.1002/cam4.71570
MLA
Bergman M, et al.. "Prognosis of Metaplastic Breast Cancer: A Population-Based Matched Cohort Study.." Cancer medicine, vol. 15, no. 2, 2026, pp. e71570.
PMID
41603205
Abstract
[PURPOSE] Metaplastic breast cancer (metBC) is a rare subtype of breast cancer known for its challenging management. The impact of this histological subtype on prognosis remains unclear.
[METHODS] Data were collected from the Swedish Cancer Registry between 2008 and 2018. Patients with metBC were matched 2:1 with breast cancer cases of no special type (NST). Survival outcomes were analyzed using cause-specific hazard models for breast cancer specific survival (BCSS) and Cox proportional-hazards models for overall survival (OS).
[RESULTS] In total, 127 metBC patients were matched 2:1 with 245 NST patients, with a median follow-up period of 54 months. When adjusted for matching variables and treatment-related characteristics, metBC was not significantly associated with either BCSS (cause-specific Hazard Ratio (HR): 1.13; 95% Confidence Interval (CI): 0.66-1.92) or OS (HR: 1.23; 95% CI: 0.83-1.82).
[CONCLUSION] With appropriate treatment, metBC may have survival outcomes comparable to NST. Larger studies with longer follow-up are needed to provide further insights.
[METHODS] Data were collected from the Swedish Cancer Registry between 2008 and 2018. Patients with metBC were matched 2:1 with breast cancer cases of no special type (NST). Survival outcomes were analyzed using cause-specific hazard models for breast cancer specific survival (BCSS) and Cox proportional-hazards models for overall survival (OS).
[RESULTS] In total, 127 metBC patients were matched 2:1 with 245 NST patients, with a median follow-up period of 54 months. When adjusted for matching variables and treatment-related characteristics, metBC was not significantly associated with either BCSS (cause-specific Hazard Ratio (HR): 1.13; 95% Confidence Interval (CI): 0.66-1.92) or OS (HR: 1.23; 95% CI: 0.83-1.82).
[CONCLUSION] With appropriate treatment, metBC may have survival outcomes comparable to NST. Larger studies with longer follow-up are needed to provide further insights.
MeSH Terms
Humans; Female; Breast Neoplasms; Prognosis; Middle Aged; Aged; Sweden; Registries; Metaplasia; Adult; Cohort Studies; Aged, 80 and over; Proportional Hazards Models